To further enhance the quality of Onco and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Constantin N. Baxevanis, the journal has updated and revised its aims and scope. All updated text is shown in italics:

Aims

Onco (ISSN: 2673-7523) is a peer-reviewed Open Access journal on oncotargets and cancer therapies, published online by MDPI. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

Scope

Onco functions as a scientific forum to integrate novel preclinical, translational and clinical cancer research with a primary focus on oncotargets and cancer therapies. The journal invites submissions of original research, reviews, editorials and commentaries covering a broad range of scientific domains, including (but not limited to):

• Cancer cell signaling;
• Cancer genetics and molecular targets;
• Cancer epigenetics and heterogeneity;
• Carcinogenesis and cancer evolution;
• Microbiome and cancer;
• Cancer metabolomics;
• Cancer biomarkers;
• Cancer dormancy;
• Novel targeted and immune cancer therapies;
• Randomized clinical trials.

Short reports can be considered, provided that they present a clear relationship with one or more of the above topics.

Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The experimental details must be provided so that the results can be reproduced.

Onco’s Editorial Board, consisting of international experts from leading institutions, oncology centers and universities in cancer research, aims to promote the evolving field of oncology.

You can see our updated and revised aims and scope at the following link: https://www.mdpi.com/journal/onco/about.